Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 30, 2014
Pharmacy Choice - Pharmacy News - October 30, 2014

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
10/30/14 - Astrazeneca Receives U.S FDA Approval For Type-2 Diabetes Medecine XIGDUO XR
LONDON- Astrazeneca plc Thursday said U.S. Food and Drug Administration approved its once-daily XIGDUO XR for type-2 diabetes in adults. XIGDUO XR, an extended release of XIGDUO, has already been approved in Australia for type-2 diabetes and XIGDUO is approved by European Union. XIGDUO XR combines dapagliflozin and metformin hydrochloride...
10/30/14 - EOS imaging Garners Marketing Approval in South Korea [Health & Beauty Close - Up]
EOS imaging has received approval from the Korean Food and Drug Administration to market the EOS system in South Korea. EOS imaging said the KFDA approval will enable the Company to continue expanding its presence in the Asia Pacific medical imaging market, which is predicted to see the highest growth globally during the next 5 years1. We are proud
10/30/14 - FDA Approves TactiCath Quartz [Health & Beauty Close - Up]
St. Jude Medical has received U.S. Food and Drug Administration approval of its TactiCath Quartz irrigated ablation catheter, technology that gives physicians a real-time, objective measure of the force that the catheter applies to a patient's heart wall during an ablation procedure. Vivek Reddy, director of electrophysiology at Mount Sinai Hospita
10/30/14 - InVivo Therapeutics Receives FDA Approval to Broaden Inclusion Criteria and Add 14 Additional Sites (20 Total) for Ongoing Pilot Trial [Global Data Point]
With this approval, the upper end of the age range has been increased from 55 to 65, the spinal cord injury level has been expanded from T3-T11 to T3-T12/L1, the enrollment window has been extended from 10 to 21 days post injury, and the Body Mass Index upper limit has been increased from 35 to 39.&# x0D;. Mark Perrin, InVivo's CEO, said, "We have
10/30/14 - Mylan Launches Generic Viramune XR®
--Mylan Inc. today announced the U.S. launch of its Nevirapine Extended-release tablets, 400 mg, which is the generic version of Boehringer Ingelheim's Viramune XR ®. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for combination antiretroviral
10/30/14 - Pfizer Receives FDA Accelerated Approval for TRUMENBA (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults
Release date- 29102014- Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted accelerated approval of TRUMENBA for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. As part of the accelerated approval process, Pfizer will complete its

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


The Diversion of Controlled Substances and the Law
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement